Singer Capital Markets appointed as Nominated Adviser to Ondine Biomedical
Singer Capital Markets is delighted to have been appointed as Nominated Adviser to Ondine Biomedical Inc. with immediate effect.
Singer Capital Markets continues to act as Corporate Broker to the Company, having been appointed as Broker in August 2022.
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.
Market Cap: £39.89 million**
Website: Click here
*Singer Capital Markets was appointed as Joint Broker on 16/08/22 alongside the Company’s existing Broker.
**Market cap as at 30/12/22